ADYX (ADYX) Stock Price & Analysis
ADYX (ADYX) rose 0.00% to USD 0 as of June 10, 2026 at 14:32 UTC, according to Nexqual real-time market data.
ADYX last closed at USD 0; the session ranged USD 0–0 on volume of 16,300 shares. Market capitalization is $580, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 14:32 UTC.
Key Statistics (as of June 10, 2026 at 14:32 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 16,300 shares |
| Market Cap | $580 |
| Exchange | PNK |
Technical Analysis (ADYX)
Nexqual's technical model rates ADYX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 14:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (ADYX)
Wall Street analysts rate ADYX "None", per Nexqual as of June 10, 2026 at 14:32 UTC.
| Consensus Rating | None |
|---|
Earnings (ADYX)
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Financials & Fundamentals (ADYX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.18 |
| Total Cash | $331,000 |
| Total Debt | $10.09M |
| Free Cash Flow | $-6.11M |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Financial Health Score (ADYX)
Nexqual rates ADYX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:32 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $331K cash vs $10M debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Mixed — No data |
Ownership (ADYX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 5.81M |
| Float | 1.03M |
| Short % of Float | +0.46% |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Leadership (ADYX)
ADYX is led by Richard Orr Esq. (age 64), President, CEO, Principal Financial Officer & Director, per Nexqual as of June 10, 2026 at 14:32 UTC.
| President, CEO, Principal Financial Officer & Director | Richard Orr Esq. (age 64) |
|---|---|
| Executive Vice President of Corporate Development & Operations | William Martin |
| Senior Director of Clinical Operations | Kimberley Hebert |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABMT | ADVANCED BIOMEDICAL TECHNOLOGIE | USD 0 | ▲ 0% |
| EMMA | Emmaus Life Sciences, Inc. | USD 0.01 | ▲ 7.84% |
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
| CDXI | CARDAX INC | USD 0 | ▲ 0% |
| ADMT | ADM Tronics Unlimited, Inc. | USD 0.07 | ▼ 1.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:32 UTC. This page is informational and not investment advice.